用于口服输送胰岛素的β-环氧德克斯/二甲葡萄糖涂层的素纳米颗粒
Yunyun Wang1, Wangdi Song1, Shengnan Xue1
1School of Chemistry and Chemical Engineering, Shihezi University/State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, Shihezi 832003, China.
International journal of biological macromolecules
|July 12, 2024
概括
这项研究引入了一种新型的双β-cyclodextrin/dialdehyde葡萄糖涂层的氨酸纳米颗粒,用于口服胰岛素的输送. 这种纳米粒子显著增强胰岛素.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 口服胰岛素可以改善糖尿病患者的生活质量.
- 目前口服胰岛素的生物可用性由于胃肠道降解而限制在≤2%.
研究的目的:
- 开发一种简单,安全和有效的纳米粒子系统,用于口服胰岛素的输送.
- 通过胃肠道增强胰岛素的稳定性和生物可用性.
主要方法:
- 开发双 β-环极/二甲 葡萄糖涂层的氨酸纳米颗粒 (β-CD-K-IN-DG).
- 在体外评估胰岛素负荷,抗酸和酶的稳定性,以及释放动力学.
- 粘液透和体外肠道上皮细胞运输的ex vivo评估.
主要成果:
- 实现了超高的胰岛素负载 (98.52%的封装效率).
- 已证明对酸性和酶性降解的保护,具有显著的低血糖效应.
- 通过旁路传输和内细胞突变显示出高粘液透率和增强的口服生物利用率 (12.27%).
结论:
- β-CD-K-IN-DG纳米颗粒为克服口服胰岛素输送障碍提供了一个有希望的策略.
- 开发的系统显著提高了胰岛素的稳定性和可用于潜在的治疗应用的生物可用性.
相关概念视频
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Insulin Formulations: Types and Delivery
184
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
184
Insulin: Biosynthesis, Chemistry, and Preparation
370
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
370
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K


